NCT04659343View on ClinicalTrials.gov

TDM for Optimized Outcome in Patients With mRCC.

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2029

Conditions
Kidney CancerRenal Cell Carcinoma MetastaticDrug ToxicityDrug Side EffectDrug Mechanism
Interventions
OTHER

Measurement of concentration of active metabolite in cancer treatment.

Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.

Trial Locations (1)

8200

RECRUITING

Department of Oncology, Aarhus University Hospital, Aarhus

All Listed Sponsors
collaborator

Herlev Hospital

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

Niels Fristrup

OTHER